Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Net Cash Flow (2016 - 2025)

Regenxbio has reported Net Cash Flow over the past 12 years, most recently at -$24.3 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$24.3 million for Q4 2025, down 2777.23% from a year ago — trailing twelve months through Dec 2025 was -$23.1 million (down 200.24% YoY), and the annual figure for FY2025 was -$23.1 million, down 200.24%.
  • Net Cash Flow for Q4 2025 was -$24.3 million at Regenxbio, down from -$20.8 million in the prior quarter.
  • Over the last five years, Net Cash Flow for RGNX hit a ceiling of $117.5 million in Q4 2021 and a floor of -$153.3 million in Q1 2022.
  • Median Net Cash Flow over the past 5 years was -$21.2 million (2022), compared with a mean of -$15.2 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 45476.7% in 2021 and later surged 392.07% in 2024.
  • Regenxbio's Net Cash Flow stood at $117.5 million in 2021, then tumbled by 118.37% to -$21.6 million in 2022, then grew by 13.17% to -$18.7 million in 2023, then soared by 104.85% to $909000.0 in 2024, then crashed by 2777.23% to -$24.3 million in 2025.
  • The last three reported values for Net Cash Flow were -$24.3 million (Q4 2025), -$20.8 million (Q3 2025), and -$50.5 million (Q2 2025) per Business Quant data.